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Articles
Community groups or mobile phone messaging to prevent 
and control type 2 diabetes and intermediate 
hyperglycaemia in Bangladesh (DMagic): 
a cluster-randomised controlled trial
Edward Fottrell, Naveed Ahmed, Joanna Morrison, Abdul Kuddus, Sanjit Kumer Shaha, Carina King, Hannah Jennings, Kohenour Akter, 
Tasmin Nahar, Hassan Haghparast-Bidgoli, A K Azad Khan, Anthony Costello, Kishwar Azad
Summary
Background Strategies are needed to prevent and control type 2 diabetes and intermediate hyperglycaemia, which 
together afect roughly a third of adults in Bangladesh. We aimed to assess the efects of mHealth and community 
mobilisation on the prevalence of intermediate hyperglycaemia and diabetes among the general adult population in 
rural Bangladesh, and to assess the efect of these interventions on the incidence of type 2 diabetes among people 
with intermediate hyperglycaemia within the study population.
Methods DMagic was a three-arm, cluster-randomised trial of participatory community mobilisation, mHealth mobile 
phone messaging, and usual care (control) in 96 villages (population roughly 125 000) in Bangladesh. Community 
mobilisation involved 18 monthly group meetings, led by lay facilitators, applying a participatory learning and action 
(PLA) cycle focused on diabetes prevention and control. mHealth involved twice-weekly voice messages over 
14 months promoting behaviour change to reduce diabetes risk. The primary outcomes were the combined prevalence 
of type 2 diabetes and intermediate hyperglycaemia in the overall population at the end of the intervention 
implementation period, and 2-year cumulative incidence of type 2 diabetes in a cohort with intermediate 
hyperglycaemia at baseline. Primary outcomes were assessed through fasting blood glucose concentrations and 2-h 
oral glucose tolerance tests among a cross-section of adults aged 30 years and older and a cohort of individuals 
identiied with intermediate hyperglycaemia. Prevalence indings are based on a cross-sectional survey at the end of 
the study; incidence indings are based on 2-year follow-up survey of a cohort of individuals identiied with 
intermediate hyperglycaemia through a cross-sectional survey at baseline. We also assessed the cost-efectiveness of 
the interventions. This trial is registered with the ISRCTN registry, number ISRCTN41083256, and is completed.
Findings The study took place between June 27, 2015, and June 28, 2018, with the PLA intervention running in 
32 villages from June, 2016, to December, 2017, and the mHealth intervention running in 32 villages from Oct 21, 
2016, to Dec 24, 2017. End-of study prevalence was assessed in 11 454 individuals and incidence in 2100 individuals. 
There was a large reduction in the combined prevalence of type 2 diabetes and intermediate hyperglycaemia in the 
PLA group compared with the control group at the end of the study (adjusted [ for stratiication, clustering, and 
wealth] odds ratio [aOR] 0·36 [0·27–0·48]), with an absolute reduction of 20·7% (95% CI 14·6–26·7). Among 
2470 adults with intermediate hyperglycaemia at baseline, 2100 (85%) were followed-up at 2 years. The 2-year 
cumulative incidence of diabetes in this cohort was signiicantly lower in the PLA group compared with control (aOR 
0·39, 0·24–0·65), representing an absolute incidence reduction of 8·7% (3·5–14·0). There was no evidence of efect 
of mHealth on combined prevalence of intermediate hyperglycaemia and diabetes (aOR 0·93, 0·74–1·16) or the 
incidence of diabetes (1·02, 0·73–1·43). The incremental cost-efectiveness ratios for PLA were INT$316 per case of 
intermediate hyperglycaemia or type 2 diabetes prevented and $6518 per case of type 2 diabetes prevented among 
individuals with intermediate hyperglycaemia.
Interpretation Our data provide strong evidence to support the use of community mobilisation based on PLA to 
prevent type 2 diabetes in this rural Bangladeshi population. Despite raising knowledge and awareness of diabetes, 
the mHealth intervention did not change disease outcomes in our population. Replication studies in other populations 
should be a priority.
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Introduction
The global prevalence of diabetes was estimated to be 9% 
among adults in 2016 and about 75% of people living 
with diabetes were in low-income and middle-income 
countries (LMICs).1 Roughly 20–30% of adults in rural 
areas of Bangladesh have abnormal fasting glucose or 
impaired glucose tolerance (together termed intermediate 
hyperglycaemia) and about 10% have diabetes,2–4 with the 
prevalence of diabetes (mostly type 2 diabetes) expected 
to reach 24–34% by 2030.5 Despite the large burden of 
diabetes and intermediate hyperglycaemia in Bangladesh, 
awareness and knowledge is low6 and efective strategies 
to prevent and control diabetes are urgently needed.
Lifestyle and non-pharmacological interventions can 
prevent or delay the onset of type 2 diabetes.7 Individual 
targeted strategies that use mobile phone technology 
(mHealth) have been shown to reduce the incidence of 
type 2 diabetes in high-risk individuals,8 but have not 
been shown to afect behaviour change and diabetes 
status among a general, rural population. Community-
based and peer support interventions might be a cost-
efective means of promoting lifestyle changes in 
LMICs,9–11 although a recent trial in India showed no 
efect on disease outcomes.12 Participatory learning and 
action (PLA) is a speciic approach to community 
mobilisation that engages communities to identify and 
address their own local problems. It has been shown to 
improve maternal and newborn survival in LMICs13 and 
might also improve child health14,15 and women’s 
reproductive health.16
Research in context
Evidence before this study
We searched PubMed, CINAHL, EMBASE, Web of Science, 
and Google Scholar for systematic reviews and published 
original studies on non-pharmacological interventions for the 
prevention and control of type 2 diabetes published up to July, 
2015, with a particular focus on mHealth and community 
mobilisation interventions in low-income and middle-income 
countries. We used the search terms “mHealth”, “digital 
interventions”, “community interventions”, “community 
groups”, “peer support”, “peer education”, and “community 
participation” in combination with “diabetes management”, 
“diabetes prevention”, and “chronic disease”. There were no 
language restrictions used. Because we wanted to understand 
both the nature of existing interventions and their effectiveness, 
we were interested in a range of studies including randomised 
controlled trials, pilot studies, case-control studies, 
and qualitative research. Previous studies have shown that 
mHealth techniques might affect health behaviours, including 
treatment adherence, weight loss, diet, and exercise, and might 
reduce the incidence of type 2 diabetes among high-risk 
individuals. Good evidence exists for group-support and peer-
support lifestyle interventions in the prevention or delaying of 
the onset of type 2 diabetes. Evidence supports the involvement 
of the community and peer support as a cost-effective means of 
promoting lifestyle changes in high-income settings, but 
research in resource-poor settings is lacking. Evidence on the 
effects of mHealth and community mobilisation on diabetes 
and related risk factors among the general population, as 
opposed to high-risk individuals, is yet to emerge from 
low-income or middle-income countries.
Added value of this study
The Bangladesh DMagic trial provides the first large-scale, 
population-level evidence concerning the effectiveness and 
cost-effectiveness of mHealth and community mobilisation 
interventions for reducing the prevalence of intermediate 
hyperglycaemia and type 2 diabetes and the incidence of type 2 
diabetes. Both interventions were acceptable to participants 
and achieved large population coverage. The mHealth 
intervention increased knowledge and awareness of type 2 
diabetes and its risk factors but had no detectable impact on 
disease outcomes. Community mobilisation using a 
participatory learning and action (PLA) approach not only 
increased knowledge and awareness of disease, but also 
significantly reduced population prevalence of diabetes and 
intermediate hyperglycaemia and the incidence of type 2 
diabetes among an intermediate hyperglycaemic cohort. 
National scale-up of PLA in Bangladesh could prevent about 
240 000 cases of type 2 diabetes and intermediate 
hyperglycaemia each year, representing savings in health-care 
costs of INT$132 million per year.
Implications of all the available evidence
The effect size of the PLA community mobilisation on blood 
glucose is compelling and was robust to sensitivity analysis. 
Based on the philosophy of Paulo Freire and building on earlier 
evidence of effectiveness on maternal, neonatal, and child 
health, ours is the first study to show effectiveness of PLA on risk 
of type 2 diabetes. The observed effect of facilitated discussion, 
mutual learning, and collective action is an important challenge 
to the individualised nature of behavioural interventions, which 
have shown little success in reducing diabetes risk in general 
populations. However, as the first study of its kind, replication 
studies in Bangladesh and elsewhere should be a research 
priority. The absence of major quantifiable changes in 
behavioural indicators related to diet, physical activity, and care 
seeking demands further exploration and hints at complex, 
ecological mechanisms of action. Lack of evidence of an effect of 
mHealth on disease outcomes in our general population 
contrasts with findings from mHealth interventions that target 
high-risk individuals in other settings.  Mixed-methods 
implementation research will be essential to better understand 
and develop population-level interventions that stimulate 
contextually specific actions to prevent and control type 2 
diabetes.
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We aimed to separately assess the efects of mHealth 
health messaging and PLA community mobilisation on 
the prevalence of intermediate hyperglycaemia and 
diabetes among the general adult population in rural 
Bangladesh, and to assess the efect of these interventions 
on the incidence of diabetes among people with inter-
mediate hyperglycaemia within the study population.
Methods
Study design and participants
The DMagic (Diabetes Mellitus: Action through 
community Groups or mHealth Information for better 
Control of population blood glucose, risk factors, 
knowledge and care seeking) trial was done in 96 villages 
(total population about 125 000) across four selected 
subdistricts (upazillas) in Faridpur district, Bangladesh, 
from June 27, 2015 to June 28, 2018. 24 villages with 
population between 750 and 2500 were selected in each 
upazilla to minimise contamination via contiguous 
borders between villages, with bufer, non-study villages 
separating most clusters. Intervention mapping at the 
beginning of the study revealed no recent or ongoing 
community-based programmes speciically designed to 
reduce the burden of non-communicable diseases, 
including type 2 diabetes.
DMagic was a three-arm, stratiied, cluster-randomised 
controlled trial in which villages were the units of 
randomisation and men and non-pregnant women 
aged 30 years and older were the units of analysis. We 
did 10 months of formative research and intervention 
development, including a baseline survey of intermediate 
hyperglycaemia, diabetes, and non-communicable disease 
risk factors, and piloting of the PLA intervention; an 
18-month intervention phase; and an 8-month post-
intervention phase, including an end-of-study survey and 
analysis. Process evaluation was done concurrently to 
describe the intervention implementation and explore 
mechanisms of efect.
The trial received ethical approval from University 
College London, London, UK (4766/002) and the 
Diabetic Association of Bangladesh, Dhaka, Bangladesh 
(BADAS-ERC/EC/t5100246). All survey participants 
provided informed consent through signature or 
thumbprint. The study protocol has been previously 
published.17 Data collection, management, and analytical 
procedures were monitored by an independent data 
monitoring committee. Trial management was also 
reviewed by an independent trial steering committee.
Randomisation and masking
At the outset of the study, we held a public orientation 
meeting in Faridpur where we obtained community 
consent and, using stratiied randomisation, the 96 villages 
were randomly allocated (1:1:1) to the mHealth intervention, 
the community mobilisation (PLA) inter vention, or 
control, with each upazilla constituting one stratum.17 The 
name of each village was written on pieces of paper, 
colour-coded by upazilla, which when folded were 
indistinguishable from each other. For each upazilla, the 
24 folded pieces of paper were placed in a bottle and then 
drawn by community leaders and representatives at the 
public orientation meeting. The irst eight villages 
per upazilla drawn from the bottle were allocated to Arm A, 
the next eight villages to Arm B, and the inal eight villages 
to Arm C. After all 96 villages had been allocated (32 to 
each trial arm), each of the three arms were randomly 
assigned to either the mHealth intervention, community 
mobilisation (PLA) intervention, or the control group by 
simultaneous drawing of arm letter and intervention 
allocation from two separate bottles. Because of the nature 
of the interventions being tested, the intervention team 
could not be masked to allocation. The data collection team 
was masked to allocation at the cluster and individual level 
during the baseline survey. Primary outcome analysis was 
done masked to allocation.
Procedures
The villages allocated to the control group received usual 
care, which in this context is care seeking in government 
or private facilities (which is often associated with out-of-
pocket payment for blood glucose testing, consultations, 
and treatments), and little or no preventative public 
health campaigning.
The mHealth intervention consisted of twice-weekly 
health behaviour and awareness-raising voice messages 
sent to participants’ mobile phones over a period of 
14 months. Message content included information on 
signs, symptoms, prevention, and care for type 2 
diabetes, and provided examples of strategies to reduce 
the risk of type 2 diabetes and its complications 
(appendix). Message content was informed by formative 
research and behaviour change theories,18,19 and was 
reviewed by medical experts. Messages were about 1 min 
duration and had various formats, including mini-
dramas, dialogues, and songs. The intervention was 
available to anyone with access to a mobile phone in the 
intervention areas (>95%) who volunteered their mobile 
phone number to community recruiters at the beginning 
of the intervention period or at 3 months into the 
intervention period.
The PLA intervention entailed monthly group meetings, 
with an average of 27 members per group, led by a lay 
facilitator who guided participants through a four-phase 
PLA cycle focused on type 2 diabetes prevention and 
control. Groups were open to all community members, 
and people with type 2 diabetes or who were deemed to 
be at high risk of non-communic able diseases were 
particularly encouraged to attend. Through the PLA cycle, 
community members identiied behavioural, social, and 
environmental threats to their health and barriers to 
healthy lifestyles, prioritised these, and then planned, 
implemented, and evaluated strategies to address these 
threats. Awareness raising, exercising in groups, local 
coordination of blood sugar testing, income generation, 
See Online for appendix
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and kitchen gardening to increase access to healthy food 
were popular strategies. Facilitators were locally recruited 
men and women who had completed higher secondary 
certiicate level of education and were recruited by the 
study team following assessment of their communication 
skills, motivation, and familiarity with the study areas. 
Facilitators received a total of 14 days’ training about PLA 
and community entry, group facilitation, and the basics of 
type 2 diabetes symptoms, prevention, and control. Each 
facilitator was responsible for running six to nine PLA 
groups each month. In addition, an equal number of 
men’s and women’s groups were established within each 
village, with a total of 122 groups facilitated by 
16 facilitators (eight men, eight women) across 32 villages. 
Joint meetings of men’s and women’s groups were 
encouraged after phase 1 of the PLA cycle (ie, after 
identiication and prioritisation of health determinants).
Training of informal health workers in the prevention 
and control of type 2 diabetes was done by the Diabetic 
Association of Bangladesh across all intervention and 
control villages during the intervention period. Project 
mapping of services in the study areas identiied all 
informal care providers (eg, village doctors, pharmacy 
owners), who were then invited to participate in service-
strengthening activities on a voluntary basis. This service 
strengthening included day-long workshops and provision 
of guidelines to cadres of largely unregulated care 
providers who had not received formal accredited training 
but might have had some degree of informal training 
through apprentices, workshops, or seminars. These 
informal care providers are typically the irst point of care 
in health seeking by individuals in rural Bangladesh.20
A sampling frame of all permanent residents aged 
30 years and older was developed from a household 
census done between Aug 21, and Oct 28, 2015. 
143 households with at least one eligible resident were 
then selected from each village by use of probability 
proportional to size sampling. A single eligible adult was 
selected from each of the 143 households for inclusion 
in the survey via simple random sampling. A baseline 
cross-sectional survey among the sampled individuals to 
obtain sociodemographic characteristics, behaviours, 
and knowledge of type 2 diabetes was done between 
Jan 23, and May 30, 2016. The survey included an 
overnight fasting blood glucose measurement in whole 
capillary blood obtained by inger prick in the middle or 
ring inger. All individuals without diagnosed type 2 
diabetes then received a 75 g glucose load dissolved in 
250 mL water. A 2-h post-prandial repeat capillary blood 
test was done to determine glucose tolerance status and 
diferentiate between individuals with intermediate 
hyperglycaemia (deined as impaired fasting glucose or 
impaired glucose tolerance) and those with type 2 
diabetes, based on WHO criteria (appendix).21 These 
baseline data were used to identify an intermediate 
hyperglycaemia cohort and to compare sociodemographic 
characteristics between the three trial groups.
Following intervention, the sampling frame was 
updated and a new random sample of adults aged 
30 years and older was selected via the same sampling 
method as used at baseline. By chance, approximately 
25% of individuals sampled for the end-of-study survey 
had also been included in the baseline survey. In 
addition, all individuals identiied with intermediate 
hyperglycaemia at baseline were followed-up in the end-
of-study survey to measure type 2 diabetes incidence in 
this cohort. An end-of-study survey of sociodemographic 
data, knowledge and behaviours, and anthropometric 
measures of weight, height, blood pressure, and fasting 
and 2 h post-prandial blood glucose measures was 
completed in the random cross-sectional sample and the 
baseline intermediate hyperglycaemia cohort between 
Jan 16, and April 30, 2018, using the same methods as at 
baseline.
Data were collected by 16 pairs of ieldworkers (one man 
and one woman in each pair) with at least secondary 
education, who underwent extensive training in survey 
methods, including supervised ield practice. Most data 
collection took place in testing centres established by the 
ield team for the purposes of the study, with additional 
data collection with pretested questionnaires taking place 
at respondents’ homes.17,22 Data collectors were supervised 
by four ield supervisors responsible for observing and 
verifying data. Data quality-control measures were 
implemented within the direct digital data capture 
system used (eg, range and consistency checks), through 
repeat measures by supervisors on a random basis, and 
where outlier data were detected on data inspection. Data 
collectors, supervisors, and managers were unaware of 
randomisation assignments at baseline, but might have 
been able to deduce assignment during data collection at 
the end of the study. Access to end-of-study data was 
restricted to the monitoring and evaluation managers 
until collection was complete, at which point the 
data were available for masked analysis by the lead 
author (EF).
Process evaluation data will be reported in detail 
elsewhere. We collected data in all four intervention 
upazillas of Faridpur district, including small group 
discussions with men and women attendees, with small 
groups of men and women with type 2 diabetes, and with 
group non-attenders. Later we met groups of men and 
women to explore triangulation and seek consensus on 
community changes. We also met with men’s and 
women’s group facilitators. In some of the groups we 
used participatory photography where they had identiied 
and represented issues of importance to them using 
mobile phone cameras. Focus group discussions were 
digitally recorded and one author (KAk) made notes 
about the indings in English and translated ield 
observation notes to English for analysis. Key themes 
around individual, household, and community change 
were compared with the theory of change drafted after 
the formative phase of research.
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Outcomes
We prespeciied two primary outcomes: the prevalence of 
intermediate hyperglycaemia and type 2 diabetes at the 
end of the study and the 2-year cumulative incidence of 
type 2 diabetes among the cohort with baseline inter-
mediate hyperglycaemia.
Secondary outcomes were mean diastolic and systolic 
blood pressure, prevalence of hypertension, hypertension 
control (among those with known hypertension), BMI, 
prevalence of overweight and obesity and abdominal 
obesity (waist to hip ratio >0·9 for men and >0·85 for 
women), health related quality of life (using EQ-5D 
score), physical activity, fruit and vegetable consumption, 
and knowledge of the causes, symptoms, complications, 
prevention and control of type 2 diabetes. Additional 
secondary outcomes among people with type 2 diabetes 
were self-awareness of diabetes status and, among 
those with known diabetes, prevalence of diabetes control, 
psychological distress (with SRQ-20 screening tool), and 
receipt of professional medical treatment or advice for 
diabetes. Full speciication of secondary outcomes and 
methods of assessment have been described previously.17
Additional pre-speciied outcomes were intervention 
costs, incremental cost-efectiveness ratios and costs 
per disability adjusted life years (DALYs) averted for 
any efective intervention, and process indicators of 
intervention coverage and qualitative assessments 
of behaviour change caused by the interventions. An 
additional outcome of diabetes-only prevalence (excluding 
intermediate hyper glycaemia) was included post-hoc. Key 
indings from the qualitative, process assessments of 
behaviour change are sumarised below, but full analyses 
are to be reported in a forthcoming publication.
Statistical analysis
We estimated that a target sample of 143 adults per 
village (total 13 728, including 10% oversample for non-
response) would provide 80% power at 95% conidence 
to detect a minimum 21·5% reduction in combined 
prevalence of type 2 diabetes and intermediate hyper-
glycaemia and 78% power to detect a 33% reduction in 
cumulative incidence of type 2 diabetes among the base-
line intermediate hyperglycaemia cohort in intervention 
clusters relative to control clusters.17
Analysis of intervention efect on the combined 
prevalence of type 2 diabetes and intermediate hyper-
glycaemia included all individuals who provided blood 
glucose measurements in the end-of-study sample 
survey. This included individuals who provided a random 
blood glucose measure on the basis of self-reported 
diagnosis of type 2 diabetes by a medical professional. 
For the cumulative incidence of type 2 diabetes among 
the intermediate hyperglycaemia cohort, the analysis 
population was all individuals for whom a baseline blood 
glucose measurement revealed intermediate hyper-
glycaemia and for whom an end-of-study blood glucose 
measurement was taken.
All analyses were done on an intention-to-treat basis. 
Comparison between interventions relative to control 
used random-efects logistic regression, allowing for the 
stratiied and clustered nature of the data. An additive 
model was used to estimate absolute diferences for the 
primary outcomes. Baseline data were examined by the 
research team for imbalance between anonymised 
randomised villages and it was agreed with the data 
monitoring committee that an apparent marginal 
diference in baseline household wealth quintiles (derived 
from principal component analysis of household assets) 
between study groups would be adjusted for in end-of-
study multivariate analyses. Prespeciied sensitivity 
analysis of primary outcomes assessed efects of missing 
data using multiple imputation and screening efects of 
individuals being included in the baseline and end-of-
study surveys. Post-hoc sensitivity analysis assessed 
sampling error, enumerator bias, and blood glucose 
measurement bias (ie, by  running analysis on continuous 
blood glucose measurements and by separately applying 
diferent arbitrary fasting blood glucose cut-ofs of 
5·5 mmol/L, 6·3 mmol/L, and 7·8 mmol/L and 2-h blood 
glucose cut-ofs of 6·8 mmol/L and 10·4 mmol/L for 
classiications of intermediate hyperglycaemia or 
diabetes). We also restricted primary outcome analysis to 
individuals with normal blood glucose levels at baseline 
who also happened to be included in the end-of-study 
survey. In view of the high prevalence of intermediate 
hyperglycaemia and type 2 diabetes and following 
recommendation from reviewers, we calculated a post-
hoc estimate of PLA efect size compared to control as 
relative risk by use of log binomial models estimated by 
generalised estimating equations with robust SEs to 
account for clustering and then calculated the number 
needed to treat (NNT). Finally, in view of the clinical 
relevance of type 2 diabetes as an outcome in its own 
right (ie, not combined with intermediate hyper-
glycaemia), we did a post-hoc analysis in which we 
assessed intervention efects on a diabetes-only outcome.
Primary analysis was done by the trial principal 
investigator (EF), who was masked to treatment allocation 
and who reported the results to the data monitoring 
committee and chair of the trial steering committee, after 
which the identities of the trial groups were revealed, and 
analysis continued unmasked. 
Prespeciied secondary outcomes analyses were based 
on complete data only. Comparative analysis used 
random-efects logistic regression for binary outcomes 
and mixed-efects linear regression for continuous 
outcomes, each allowing for clustering and upazilla 
stratiication. Continuous outcome measures with a 
skewed distribution were log-transformed before 
regression analysis. All quantitative analyses were done 
using STATA/SE version 15.1.
Intervention implementation and coverage was 
estimated from process evaluation data. Total cost and 
cost-efectiveness analysis of the DMagic interventions 
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was done initially from a provider (health system) 
perspective, including costs to the programme provider 
and public health-care providers (ie, costs associated with 
increasing service demand and utilisation). Incremental 
cost-efectiveness ratios were calculated in terms of cost 
per case of intermediate hyperglycaemia and type 2 
diabetes prevented in the general population sample, cost 
per case of type 2 diabetes prevented among the high-risk 
cohort with intermediate hyperglycaemia at baseline, 
and costs per DALY averted. All costs were adjusted for 
inlation, discounted at 3% per year, and converted to 2018 
international dollars (INT$). We calculated DALYs averted 
using the Global Burden of Disease study approach 
(appendix);23,24 a detailed description of the economic 
evaluation methodology is presented elsewhere.25 Since 
our interventions and evaluation of them were population 
based (as opposed to an individual-level study) and, for the 
most part, we did not follow up the same individuals from 
baseline to end of study, we were not able to estimate 
quality-adjusted life years (QALYs) gained.
This trial is registered with the ISRCTN registry, number 
ISRCTN41083256, and is completed. The trial was regis-
tered on March 30, 2016, which was after the initial phase 
of the study but before any intervention delivery began. In 
view of the study design, it was not feasible to register the 
trial before this date, since cluster selection was purposeful 
(ie, based on population size and non-contiguous borders 
with other clusters) and identiication of clusters was 
integral to project design and planning.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing 
the report. The corresponding author had full access to 
all the data in the study and had inal responsibility for 
the decision to submit for publication.
Results
All 96 villages agreed to participate and were randomly 
assigned, 32 to each of the three trial groups. Survey 
and/or anthropometric baseline data were collected from 
12280 (89·5%) of 13 684 individuals between Jan 23, and 
May 30, 2016. The target sample was slightly smaller than 
expected because two villages only had 128 and 114 eligible 
individuals living in separate households. From the 
baseline survey, 2470 individuals were identiied with 
Control mHealth PLA
Cluster level
Villages (clusters) 32 32 32
Mean village population 
aged ≥30 years (SD)
521 (189) 551 (152) 548 (225)
Mean number of 
households (SD)
269 (97) 282 (79) 285 (112)
Individual level
Total participants who 
completed survey
4048 4071 4021
Age, years
30–39 1391 (34%) 1329 (33%) 1388 (35%)
40–49 991 (24%) 1068 (26%) 992 (25%)
50–59 767 (19%) 765 (19%) 761 (19%)
60–69 648 (16%) 659 (16%) 610 (15%)
70–100 251 (6%) 250 (6%) 270 (7%)
Sex
Men 1950 (48%) 1845 (45%) 1889 (47%)
Women 2098 (52%) 2226 (55%) 2132 (53%)
Education
None 2116 (52%) 1950 (48%) 1905 (47%)
Primary 921 (23%) 852 (21%) 1004 (25%)
Secondary 989 (24%) 1231 (30%) 1086 (27%)
Tertiary 22 (1%) 38 (1%) 26 (1%)
Literacy
Literate 1455 (36%) 1649 (41%) 1561 (39%)
Illiterate 2593 (64%) 2422 (59%) 2460 (61%)
Marital status
Married 3528 (87%) 3574 (88%) 3530 (88%)
Not married 520 (13%) 497 (12%) 491 (12%)
Religion
Muslim 3660 (90%) 3674 (90%) 3666 (91%)
Other 388 (10%) 397 (10%) 355 (9%)
Occupation
Not working 2216 (55%) 2323 (57%) 2164 (54%)
Manual labour 1362 (34%) 1296 (32%) 1376 (34%)
Non-manual labour 468 (12%) 452 (11%) 481 (12%)
Missing data 2 (<1%) 0 0
Wealth quintile
Most poor 845 (21%) 910 (22%) 676 (17%)
Very poor 781 (19%) 896 (22%) 768 (19%)
Poor 822 (20%) 821 (20%) 798 (20%)
Less poor 855 (21%) 722 (18%) 826 (21%)
Least poor 745 (18%) 722 (18%) 953 (24%)
(Table 1 continues in next column)
Control mHealth PLA
(Continued from previous column)
Total participants with 
baseline data for 
glycaemic status*
4070 4063 4054
Glycaemic status
Normal 2860 (70%) 2816 (69%) 2801 (69%)
Impaired fasting 
glucose†
200 (5%) 186 (5%) 203 (5%)
Impaired glucose 
tolerance†
632 (16%) 655 (16%) 594 (15%)
Diabetes‡ 378 (9%) 406 (10%) 456 (11%)
PLA=participatory learning and action. *Glycaemic status missing for 
38 participants in the control group, 30 participants in the mHealth group, and 
25 participants in the PLA group (excluded from totals). †Intermediate 
hyperglycaemia was defined as impaired fasting glucose or impaired glucose 
tolerance. ‡Based on blood glucose measurement or self-reported previous 
medical diagnosis.21
Table 1: Baseline characteristics
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intermediate hyperglycaemia. Baseline characteristics 
were similar among all study groups (table 1, appendix), 
apart from a small diference in household wealth (higher 
in PLA villages), which was later adjusted for in 
multivariate analyses.
End-of-study data were collected from 11 454 (83·7%) of 
13 687 individuals between Jan 16, and April 30, 2018. The 
end-of-study cross-sectional sample was similar in terms 
of sociodemographic characteristics to the baseline 
sample and between study groups (appendix). Of the 
2470 individuals with intermediate hyperglycaemia at 
baseline, 2100 were followed-up (85%; igure 1). Non-
responders were more likely to be men (1712 [23%] of 
7520 men vs 721 [9%] of 7854 women; p<0·0001; igure 1) 
and men non-responders were younger than men 
responders (mean diference 2·0 years; p<0·0001), 
whereas women non-responders were slightly older than 
women responders (mean diference 3·1 years; 
p<0·0001). The same patterns of non-response were seen 
across all study groups.
Exposure to the interventions was fairly high (table 2). 
In the mHealth intervention group, 2613 (61%) of 
4320 villagers reported ever receiving a mobile phone 
message; in the PLA group, 3136 (74%) of 4247 reported 
ever participating in a group.
At the end-of-study survey, the combined prevalence 
of type 2 diabetes and intermediate hyperglycaemia was 
signiicantly lower in the PLA group compared with the 
control group (table 3, igure 2). The 2-year cumulative 
incidence of type 2 diabetes among the intermediate 
hyperglycaemia cohort in the PLA group compared with 
the control group was also signiicantly reduced (table 3, 
igure 2). Our post-hoc analysis of the efect on type 2 
diabetes prevalence only (ie, not combined with 
intermediate hyperglycaemia) showed that the PLA 
intervention reduced the prevalence of type 2 diabetes 
by 48% relative to control (305 [8%] of 3757 vs 493 [13%] 
of 3821; adjusted [stratiied, clustered design, and 
wealth] odds ratio [aOR] 0·52, 0·38–0·71; p<0·0001). 
There was no evidence of an efect of the mHealth 
intervention on the combined prevalence of type 2 
diabetes and inter mediate hyperglycaemia or the 
incidence of type 2 diabetes in the intermediate 
hyperglycaemia cohort compared with control villages 
Figure 1: Trial profile
Anthropometry includes all physical measures—ie, blood glucose, blood pressure, weight, height, and waist and hip circumferences. PLA=participatory learning and action. *Other reasons were 
physical or mental disability or severe illness preventing participation, incarceration, or temporary residence only.
End-of-study cross-sectional 
survey (target n=4576)
Response
3785 (83%) anthropometry 
  and survey
 44 (1%) anthropometry 
  only
 1 (<1%) survey only
Non-response
 49 (1%) died
 18 (<1%) were pregnant
 265 (6%) had migrated
 182 (4%) refused
 216 (5%) were not found
 16 (<1%) other reasons* 
Intermediate 
hyperglycaemia cohort
follow-up (n=832)
Response
 704 (85%) anthropometry
  and survey
 9 (1%) anthropometry 
  only
Lost to follow-up
 18 (2%) died
 2 (<1%) were pregnant
 41 (5%) had migrated
 24 (3%) refused
 29 (3%) were not found
 5 (1%) other reasons* 
End-of-study cross-sectional 
survey (target n=4566)
Response
3797 (83%) anthropometry 
  and survey
 15 (<1%) anthropometry 
  only
 5 (<1%) survey only
Non-response
 53 (1%) died
 23 (1%) were pregnant
 233 (5%) had migrated
 199 (4%) refused
 220 (5%) were not found
 21 (<1%) other reasons*
Intermediate 
hyperglycaemia cohort
follow-up (n=841)
Response
 714 (85%) anthropometry
  and survey
 5 (1%) anthropometry 
  only
Lost to follow-up
 16 (2%) died
 4 (<1%) were pregnant
 47 (6%) had migrated
 21 (2%) refused
 30 (4%) were not found
 4 (<1%) other reasons* 
End-of-study cross-sectional 
survey (target n=4545)
Response
3786 (83%) anthropometry 
  and survey
 12 (<1%) anthropometry 
  only
 9 (<1%) survey only
Non-response
 57 (1%) died
 14 (<1%) were pregnant
 244 (5%) had migrated
 180 (4%) refused
 229 (5%) were not found
 14 (<1%) other reasons* 
Intermediate 
hyperglycaemia cohort
follow-up (n=797)
Response
 666 (84%) anthropometry
  and survey
 2 (<1%) anthropometry 
  only
Lost to follow-up
 19 (2%) died
 2 (<1%) were pregnant
 35 (4%) had migrated
 38 (5%) refused
 31 (4%) were not found
 4  (1%) other reasons* 
Baseline cross-sectional 
survey (target n=4576)
4010 (88%) anthropometry 
  and survey
 60 (1%) anthropometry 
  only
 38 (1%) survey only
 468 (10%) no response
 832 individuals identified 
  with intermediate
  hyperglycaemia
Baseline cross-sectional 
survey (target n=4561)
4044 (89%) anthropometry 
  and survey
 22 (<1%) anthropometry 
  only
 27 (1%) survey only
 468 (10%) no response
 841 individuals identified 
  with intermediate
  hyperglycaemia
Baseline cross-sectional 
survey (target n=4547)
3993 (88%) anthropometry 
  and survey
 58 (1%) anthropometry 
  only
 28 (1%) survey only
 468 (10%) no response
 797 individuals identified 
  with intermediate
  hyperglycaemia
32 villages randomly 
 assigned to control
32 villages randomly 
 assigned to mHealth
32 villages randomly 
 assigned to PLA 
 community mobilisation
        96 villages (clusters) enrolled
52 352 permanent residents aged ≥30 years (eligible population)
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(table 3, igure 2). There was also no evidence of an 
efect of the mHealth intervention on the prevalence of 
type 2 diabetes alone in our post-hoc analysis (563 [15%] 
of 3797 vs 493 [13%] of 3821; adjusted [stratiied, 
clustered design, and wealth] aOR 1·18, 0·95–1·48; 
p=0·139).
Increases in ability to report one or more valid causes, 
symptoms, complications, and strategies for prevention 
and control of diabetes were observed in both intervention 
groups compared with control, with the efect consistently 
greatest in the PLA group (table 4). Self-awareness of 
diabetes status among individuals identiied as having type 
2 diabetes by blood glucose testing was ive-times higher 
in the PLA group than in the control group (aOR 5·09, 
2·95–8·79; p<0·0001), but the smaller increase in the 
mHealth group compared with control was not signiicant 
(aOR 1·44, 0·94–2·19; p=0·092). Improvements in 
diabetes control among people with known diabetes in the 
intervention groups compared with control were not 
signiicant and there was no intervention efect on receipt 
of professional care for diabetes among those aware of 
their disease (table 4).
There was no evidence of an efect of either intervention 
on blood pressure, overweight and obesity, or self-reported 
physical activity or fruit and vegetable consumption 
(table 4). Overall quality-of-life score did not difer between 
study groups, and the crude signiicant diference in self-
rated health measured on a scale of 0 (worst health) to 100 
(best health) between the PLA and control groups was 
attenuated and non-signiicant when adjusted for 
household wealth (table 4).
Prespeciied sensitivity analyses including adjustment 
for a possible screening efect among individuals included 
in the baseline and end-of-study surveys and multilevel 
multiple imputations for missing blood glucose measure-
ments had negligible efect on the primary analyses 
(appendix).
In view of the indings for the PLA intervention, we did 
additional post-hoc sensitivity analyses. First, we assessed 
potential sampling error and imbalances in key socio-
demographic characteristics between study groups by 
running a predictive regression of our primary outcomes 
on sociodemographic characteristics at base line and then 
checked whether the signiicant variables in this predictive 
regression difered between treatment groups. Apart from 
wealth quintiles, which we had prespeciied as a covariate 
in our model, no other sociodemographic measures were 
signiicantly diferent between treatment groups, lending 
support to our primary indings (data not shown) and 
suggesting that our random sampling approach was 
efective and consistent across study groups.
We then explored potential blood glucose measurement 
biases and errors. We checked the efect of PLA on the 
continuous fasting and 2-h blood glucose measures, which 
showed signiicant reductions in mean population glucose 
compared with control (appendix). We also ran a series of 
regression models on the primary outcomes using 
diferent, arbitrary cut-of points for categorisation of 
intermediate hyperglycaemia and type 2 diabetes; again, 
our inding of a strong association of reduced prevalence 
and incidence with PLA exposure remained irrespective of 
cut-of values used (data not shown). Finally, to rule out 
potential enumerator efects (ie, potential bias in 
PLA (n=4247) mHealth (n=4320) Control (n=4292)
Ever participated in PLA community group 3136 (74%) 1 (<1%) 1 (<1%)
Knows someone who attended PLA 
community group
3046 (72%) 10 (<1%) 0 (<1%)
Ever received mHealth message 55 (1%) 2613 (60%) 7 (<1%)
Knows someone who received mHealth 
messages
32 (1%) 2845 (66%) 6 (<1%)
Data are n (%). PLA=participatory learning and action.
Table 2: Intervention coverage process indicators
Control mHealth PLA
Population prevalence of intermediate hyperglycaemia and diabetes*†
Total population 3821 3797 3757
Normoglycaemic 1960 (51·3%) 2003 (52·8%) 2686 (71·5%)
Diabetes or intermediate hyperglycaemic 1861 (48·7%) 1794 (47·2%) 1071 (28·5%)
Relative difference (odds ratio [95% CI])
Unadjusted (allowing for stratified 
clustered design)
Reference 0·94 (0·75–1·18; 
p=0·611)
0·37 (0·27–0·49; 
p<0·0001)
Adjusted for household wealth 
quintile and allowing for stratified 
clustered design
Reference 0·93 (0·74–1·16; 
p=0·513)
0·36 (0·27–0·48; 
p<0·0001)
Absolute risk difference, % points (95% CI)
Unadjusted (allowing for stratified 
clustered design
Reference –1·4 (–6·9 to 4·1; 
p=0·626)
–20·1 (–26·1 to –14·0; 
p<0·0001)
Adjusted for household wealth 
quintile and allowing for stratified 
clustered design
Reference –1·7 (–7·3 to 3·9; 
p=0·542)
–20·7 (–26·7 to –14·6; 
p<0·0001)
2 year cumulative incidence among intermediate hyperglycaemic cohort‡
Total population 712 717 665
Normoglycaemic 249 (35·0%) 280 (39·1%) 407 (61·2%)
Intermediate hyperglycaemic 337 (47·3%) 315 (43·9%) 199 (29·9%)
Diabetes 126 (17·7%) 122 (17·0%) 59 (8·9%)
Relative difference (odds ratio [95% CI])
Unadjusted (allowing for stratified 
clustered design)
Reference 0·99 (0·70–1·39; 
p=0·941)
0·41 (0·24–0·68; 
p=0·0005)
Adjusted for household wealth 
quintile and allowing for stratified 
clustered design
Reference 1·02 (0·73–1·43; 
p=0·912)
0·39 (0·24–0·65; 
p=0·0003)
Absolute risk difference, % points (95% CI)
Unadjusted (allowing for stratified 
clustered design)
Reference –0·04 (–5·3 to 5·3; 
p=0·987)
–8·4 (–13·8 to –3·0; 
p=0·0023)
Adjusted for household wealth 
quintile and allowing for stratified 
clustered design
Reference 0·36 (–4·7 to 5·5; 
p=0·889)
–8·7 (–14·0 to –3·5; 
p=0·0011)
Data are n or n (%), unless otherwise indicated. All p-value comparisons are versus control. PLA=participatory learning 
and action. *Coefficient of variation for diabetes and intermediate hyperglycaemia is 0·346. †Anthropometry 
participants with missing blood glucose data: eight in the control group, 15 in the mHealth group, and 41 in the PLA 
group. ‡Anthropometry participants with missing blood glucose data: one in the control group, two in the mHealth 
group, and three in the PLA group.
Table 3: Primary outcome measures at end of study
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ieldworker measurements), we included enumerator 
identiiers as ixed efects in our regression of intervention 
exposure and fasting and 2 h blood glucose, treated as 
continuous outcomes. By doing so were able to show that 
our indings were robust to the inclusion of enumerator 
ixed efects (appendix) and that the enumerator ixed 
efects were statistically null (fasting blood glucose 
enumerator F-test=0·002, p=0·9642; 2 h blood glucose 
enumerator F-test=0·966, p=0·3257).
We also restricted our incidence analysis to 
1457 individuals with normoglycaemic blood glucose 
measurements at baseline who happened to also be 
included in our end-of-study sample. Our random-efects 
regression indings showed a 72% reduction in the 
combined incidence of intermediate hyperglycaemia and 
type 2 diabetes among normoglycaemic individuals in 
PLA villages relative to control (OR 0·28, 0·19–0·42; 
p<0·0001), suggesting that PLA was also efective among 
a normoglycaemic population.
For the combined prevalence outcome, the relative risk 
for PLA compared with control was 0·61 (95% CI 
0·50–0·73), with an NNT of 4·75 (95% CI 3·71–6·61). 
For the 2 year cumulative incidence outcome, the relative 
risk was 0·49 (0·31–0·80), with an NNT of 10·68 
(7·02–22·32).
Both interventions were delivered as per our published 
protocol, although the mHealth intervention started 
about 4 months later than originally planned and thus 
ran for just 14 months (instead of 18 months) due to 
technical and bureaucratic delays in establishing a 
system to deliver messages. The 122 PLA groups ran 
from June, 2016, to December, 2017, with a population 
coverage of one group per 342 people. In the PLA group, 
3136 (74%) of 4247 people in the end-of-study survey 
population reported participating in group meetings 
(table 2). Repeat attendance at groups was very high, with 
about 90% of attenders participating in multiple 
meetings (data not shown). Roughly 9000 individuals 
(22% of the total population of around 41 667) provided 
their mobile phone numbers to receive the mHealth 
intervention and messages were delivered to about 
7400 (82%) of these (around 51% of eligible adults). A 
total of 120 diferent messages were developed and sent 
between Oct 21, 2016 and Dec 24, 2017. An average of 60% 
of the irst 26 messages were received; thereafter we 
improved the delivery systems, which increased receipt 
to 86% for the remaining 94 messages. More than 50% of 
100 randomly selected message recipients who 
participated in a process evaluation survey reported 
sharing messages with others and two-thirds of the end-
of-study population in mHealth villages received or knew 
someone who received the messages (table 2). 
Contamination between trial groups was minimal.
Details of our qualitative indings will be reported 
elsewhere. In summary, these data suggest that changes 
occurred at the individual, household, and community 
levels in response to the PLA intervention. As awareness 
of how to prevent type 2 diabetes increased, and 
individuals were motivated to change their diets, reporting 
reduced rice, oil, sugar, and salt consumption and 
increased consumption of a variety of vegetables. Kitchen 
gardens were encouraged by groups and increased access 
to vegetables. Both attenders and non-attenders reported 
an increase in intentional physical activity in PLA 
intervention areas, particularly among women, as it 
became more acceptable for them to walk in groups to 
prevent or control diabetes. Formative data show that few 
women felt comfortable to walk outside their households 
before either intervention. In our end-of-study survey, the 
median self-reported time spent doing physical activity 
each week was 60 min greater in PLA clusters than in 
control clusters (ratio of geometric mean of activity time 
1·12 [95% CI 0·88–1·43]), although this diference was 
not signiicant when we accounted for the stratiied, 
clustered survey design. When men and women from the 
same household participated in groups, behaviour change 
Figure 2: Allocation box-plots showing (A) a cluster-level summary of 
intermediate hyperglycaemia and diabetes at end of study and 
(B) cluster-level 2 year cumulative incidence of diabetes among the 
hyperglycaemic cohort
Box-plot shows median, minimum and maximum values and interquartile range.
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was easier to initiate and sustain. PLA groups and their 
activities made community members feel in control of 
their health and able to prevent diabetes. The PLA 
intervention also destigmatised blood glucose testing and 
healthy behaviours such as physical activity, reduced or no 
sugar in tea, and healthy eating while socialising.
Total and average annual costs of the PLA intervention 
were INT$601 484 and $240 594, respectively. Total and 
average annual costs of the mHealth intervention were 
$312 630 and $125 052, respectively. The average annual 
costs of the PLA and mHealth per beneiciary (adults 
≥30 years) covered were $14 and $7, respectively, with 
Study group Unadjusted coefficient or odds ratio* Adjusted coefficient or odds ratio†
PLA (n=3798) mHealth 
(n=3812)
Control 
(n=3829)
PLA vs control mHealth vs control PLA vs control mHealth vs control
Mean diastolic blood pressure 
(mm Hg)
73·8 (11·2) 72·9 (11·2) 73·9 (11·2) –0·25 (–1·78 to 1·28; 
p=0·748)
–1·12 (–2·59 to 0·35; 
p=0·135)
–0·50 (–2·05 to 1·05; 
p=0·526)
–1·18 (–2·58 to 0·22; 
p=0·098)
Mean systolic blood pressure 
(mm Hg)
125·3 (19·6) 124·4 (20·0) 125·5 (20·8) –0·19 (–2·54 to 2·17; 
p=0·877)
–1·05 (–3·46 to 1·35; 
p=0·391)
–0·53 (–2·90 to 1·83; 
p=0·661)
–1·10 (–3·44 to 1·25; 
p=0·360)
Hypertension 958 (25%) 854 (22%) 899 (23%) 1·08 (0·86 to 1·35; 
p=0·516)
0·94 (0·78 to 1·14; 
p=0·517)
1·02 (0·81 to 1·29; 
p=0·837)
0·93 (0·77 to 1·14; 
p=0·483)
Hypertension control (among those 
with known hypertension)
131/332 
(39%)
122/313 
(39%)
90/258 
(35%)
1·21 (0·79 to 1·87; 
p=0·375)
1·12 (0·79 to 1·59; 
p=0·523)
1·21 (0·78 to 1·87; 
p=0·389)
1·13 (0·80 to 1·60; 
p=0·501)
Mean BMI (kg/m²) 22·0 (3·6) 21·9 (3·6) 21·9 (3·6) 0·08 (–0·21 to 0·38; 
p=0·572)
–0·05 (–0·28 to 0·17; 
p=0·631)
–0·09 (–0·39 to 0·20; 
p=0·543)
–0·09 (–0·29 to 0·12; 
p=0·410)
Overweight or obese (waist:hip ratio 
>0·9 for men and >0·85 for women)
1341 (35%) 1265 (33%) 1326 (35%) 1·03 (0·88 to 1·20; 
p=0·720)
0·94 (0·83 to 1·06; 
p=0·286)
0·94 (0·80 to 1·11; 
p=0·459)
0·92 (0·82 to 1·03; 
p=0·151)
Abdominal obesity 1964 (52%) 1952 (51%) 1922 (50%) 1·05 (0·74 to 1·48; 
p=0·791)
1·03 (0·73 to 1·46; 
p=0·851)
0·98 (0·70 to 1·37; 
p=0·914)
1·02 (0·72 to 1·44; 
p=0·916)
Median EQ-5D‡§ 0·80 
(0·73–1·0)
0·85 
(0·73–1·0)
0·80 
(0·73–1·0)
0·03 (–0·02 to 0·08; 
p=0·253)
–0·01 (–0·06 to 0·04; 
p=0·687)
0·03 (–0·02 to 0·07; 
p=0·261)
–0·02 (–0·06 to 0·03; 
p=0·471)
Mean self-rated health§ 77·9 (15·5) 76·7 (16·0) 74·5 (16·1) 3·28 (0·37 to 6·19; 
p=0·027)
2·12 (–0·78 to 5·02; 
p=0·153)
2·76 (–0·16 to 5·68; 
p=0·064)
1·96 (–0·97 to 4·88; 
p=0·189)
Median SRQ-20 score among adults 
aged ≥30 years with self-reported 
diabetes
8 (5–12); 
n=137
6 (4–9); 
n=144
8 (5–13);  
n=94
–0·004 (–0·20 to 0·19; 
p=0·971)
–0·17 (–0·36 to 0·02; 
p=0·085)
0·006 (–0·19 to 0·20; 
p=0·949)
–0·16 (–0·35 to 0·03; 
p=0·105)
Ability to report one or more valid 
cause of diabetes§
3646 (96%) 2981 (78%) 2153 (57%) 36·7 (18·2 to 73·7; 
p<0·0001)
3·72 (2·06 to 6·73; 
p<0·0001)
35·7 (17·7 to 71·9; 
p<0·0001)
3·77 (2·05 to 6·91; 
p<0·0001)
Ability to report one or more valid 
symptom of diabetes§
3659 (96%) 3205 (84%) 2452 (65%) 25·1 (11·8 to 53·2; 
p<0·0001)
4·34 (2·07 to 9·10; 
p=0·0001)
24·0 (11·3 to 50·9; 
p<0·0001)
4·37 (2·07 to 9·24; 
p=0·0001)
Ability to report one or more valid 
complication of diabetes§
3649 (96%) 3084 (81%) 2161 (57%) 36·5 (18·5 to 72·0; 
p<0·0001)
5·29 (2·58 to 10·9; 
p<0·0001)
35·4 (17·8 to 70·4; 
p<0·0001)
5·42 (2·60 to 11·3; 
p<0·0001)
Ability to recognise one or more valid 
complication of diabetes when 
prompted§
3723 (98%) 3367 (89%) 2932 (77%) 19·7 (8·24 to 46·9; 
p<0·0001)
3·87 (1·49 to 10·1; 
p=0·0056)
18·3 (7·66 to 43·9; 
p<0·0001)
3·88 (1·47 to 10·2; 
p=0·0063)
Ability to report one or more valid 
way to prevent diabetes§
3608 (95%) 3294 (87%) 2626 (69%) 10·6 (5·74 to 19·4; 
p<0·0001)
4·28 (2·10 to 8·68; 
p=0·0001)
10·0 (5·44 to 18·5; 
p<0·0001)
4·31 (2·10 to 8·85; 
p=0·0001)
Ability to report one or more valid 
way to control diabetes§
3619 (95%) 3354 (88%) 2796 (74%) 8·81 (4·64 to 16·7; 
p<0·0001)
3·94 (1·92 to 8·08; 
p=0·0002)
8·36 (4·42 to 15·8; 
p<0·0001)
3·93 (1·90 to 8·12; 
p=0·0002)
Diabetes control among those with 
known of diabetes
68/123 
(55%)
57/134 
(43%)
33/86 
(38%)
2·17 (0·97 to 4·87; 
p=0·060)
1·22 (0·51 to 2·94; 
p=0·657)
2·24 (0·97 to 5·16; 
p=0·058)
1·21 (0·50 to 2·92; 
p=0·666)
Self-reported awareness of diabetes 
status among all those identified as 
having diabetes by objective blood 
glucose test
143/342 
(42%)
156/652 
(24%)
100/580 
(17%)
5·10 (2·97 to 8·76; 
p<0·0001)
1·42 (0·91 to 2·20; 
p=0·119)
5·09 (2·95 to 8·79; 
p<0·0001)
1·44 (0·94 to 2·19; 
p=0·092)
Receipt of professional treatment or 
advice for diabetes among those with 
diabetes and aware of their status
114/143 
(80%)
128/156 
(82%)
84/100 
(84%)
0·85 (0·35 to 2·02; 
p=0·708)
0·97 (0·43 to 2·19; 
p=0·947)
0·78 (0·32 to 1·92; 
p=0·584)
0·93 (0·41 to 2·13; 
p=0·873)
Average ≥150 min physical activity 
per week§
2844 (75%) 2891 (76%) 2923 (77%) 0·84 (0·54 to 1·30; 
p=0·435)
1·00 (0·63 to 1·59; 
p=0·993)
0·83 (0·53 to 1·30; 
p=0·418)
0·98 (0·62 to 1·57; 
p=0·945)
Mean number of portions of fruit and/ 
or vegetables consumed per day¶
4·0 (2·3) 3·4 (1·6) 3·6 (1·6) 0·35 (–0·11 to 0·81; 
p=0·133)
–0·18 (–0·54 to 0·18; 
p=0·335)
0·29 (–0·10 to 0·69; 
p=0·143)
–0·19 (–0·53 to 0·15; 
p=0·274)
Data are mean (SD), median (IQR), n/N (%), or n (%), unless otherwise indicated. Measures of effect are beta coefficients where the measure is continuous (eg, mean or median) and are odds ratios where the 
measure is %. PLA=participatory learning and action. SRQ-20=Self-Reporting Questionnaire 20-Item. *Accounting for stratified clustered design . †Adjusted for household wealth quintile and accounting for 
stratified, clustered design. ‡EuroQol-5D (EQ-5D) using UK tariffs. §Survey totals PLA=3795; mHealth=3802; and control=3786. ¶Survey totals PLA=3792; mHealth=3802; control=3777.
Table 4: Secondary outcome measures at end of study
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costs per total population (all ages) being $6 and $3, 
respectively. The incremental cost-efectiveness ratios for 
PLA were $316 per case of intermediate hyperglycaemia 
or type 2 diabetes prevented (or $124 per DALY averted) 
and $6518 per case of type 2 diabetes prevented 
(or $2551 per DALY averted) among individuals with 
intermediate hyperglycaemia at baseline.
Discussion
We assessed two community interventions to prevent and 
control type 2 diabetes and intermediate hyperglycaemia 
in rural Bangladesh. Facilitated PLA community 
mobilisation led to large, signiicant reductions in the 
combined prevalence of type 2 diabetes and intermediate 
hyperglycaemia and 2-year incidence of type 2 diabetes 
among an intermediate hyperglycaemia cohort. The 
mHealth inter vention had no efect on diabetes status. 
Both inter ventions were associated with improvements in 
diabetes knowledge, but had no apparent impact on blood 
pressure, overweight and obesity, or on recalled fruit and 
vegetable consumption or physical activity.
The efect size of the PLA community mobilisation on 
blood glucose is surprising, especially in the absence of 
major quantiiable changes in behavioural indicators 
related to diet, physical activity, and care seeking. We 
therefore did several additional data checks and 
sensitivity analyses to identify alternative explanations 
for the observed efects. However, our results are robust 
to examinations for sampling errors, enumerator efects, 
measurement biases, and response bias. Furthermore, 
the observed efectiveness of PLA on mean population 
blood glucose measures suggests that our indings are 
not an artefact of blood glucose cut-of values used. The 
efectiveness of the intervention on normoglycaemic 
individuals adds to the evidence of PLA efectiveness in 
the general population and not only high-risk individuals. 
Overall, therefore, our indings are compelling, but 
replication is needed in other populations in Bangladesh 
and elsewhere.
Although very diferent in terms of mode of delivery 
and, ultimately, impact, there was substantial overlap in 
terms of the content and focus of our mHealth and PLA 
interventions. Our indings contribute to existing 
literature on mHealth interventions in LMICs. Despite 
potential for relatively low-cost scalability,26 mHealth 
interventions have often been criticised for a lack of 
robust assessment in terms of health outcomes.27,28 Our 
twice-weekly voice message intervention had a strong 
basis in behaviour change theory, high population 
coverage (albeit lower than the PLA intervention), and 
important impacts on knowledge and awareness of type 2 
diabetes, but did not change disease outcomes at the 
population level. Our indings on mHealth efectiveness 
difer from those reported by Ramachandran and 
colleagues,8 who noted signiicant reductions in the 
incidence of type 2 diabetes among urban working men 
with impaired glucose tolerance who received prescribed 
lifestyle changes followed by tailored text messages in 
southeast India. Our indings also difer to those reported 
by Islam and colleagues,29 who observed improved 
glycaemic control among patients with type 2 diabetes 
randomly assigned to receive mobile text messages over 
a 6-month period.29 Although details of the intervention 
and trial design of Islam and colleagues’ study are 
unclear, diferences in population demographics of 
Ramachandran and colleagues’ and Islam and colleagues’ 
trials, the individual-level randomisation, and delivery of 
text messages to individuals receiving care are notable 
between these studies and ours. It is also possible that 
the delayed start, slightly shorter-than-planned mHealth 
delivery period, and temporary problems in delivering 
messages to about 40% of registered mobiles at the 
beginning of the study might have reduced the 
efectiveness of our intervention.
That disease outcome changes were only apparent in 
the PLA group suggests wider beneits of participatory 
interventions beyond the provision of information and 
modelled behaviour employed in our mHealth inter-
vention. This inding builds on existing evidence of the 
efectiveness of PLA on maternal, neonatal, and child 
health,13 and ours is the irst assessment of this method 
for a non-communicable disease. Our inter vention 
difers from the recent peer-support lifestyle intervention 
in Kerala, which improved physical activity and dietary 
practices but did not afect the incidence of type 2 
diabetes among a high-risk cohort.12 First, unlike our 
measurement of population-level efects, the Kerala 
outcomes were only measured among the high-risk 
individuals who, in the intervention group, had been 
assigned to group support. It is possible that our 
intervention improved certain secondary outcomes such 
as diet and physical activity among high-risk sub-groups 
that are not apparent in general population measurement 
from only survey questions. Second, the peer-support 
intervention seems to be education-focused and targeted 
to a high-risk cohort, unlike our inclusive PLA approach. 
Finally, better education and literacy indices among 
the Kerala study population notwithstanding, in the 
patriarchal context of Bangladesh we implemented 
separate groups for men and women, whereas the Kerala 
study implemented mixed-sex groups, which might have 
afected their efectiveness.
Our study has several limitations. Although based on 
WHO STEPS and the Demographic and Health Survey 
instruments previously applied in Bangladesh and pilot 
tested before any data collection, large parts of our survey 
tools, such as for knowledge of diabetes, were developed 
for this study and were not formally validated in our 
study population. Our measure of physical activity was 
crude and based on recall and analysed as a binary 
measure of at least 150 min per week; this approach 
might have missed signiicant changes in the intensity of 
population exercise between groups. We did not do a 
detailed food consumption survey, allowing detailed 
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assessment of changes in consumption of certain foods, 
such as sugar-sweetened beverages. The large efects of 
PLA on disease without apparent changes in common 
diabetes risk factors suggests a complex mechanism of 
action. Perhaps several small changes in lifestyle and diet 
combined to produce a strong cumulative efect on blood 
sugar. Dietary and physical activity behaviour change was 
self-reported in process evaluation data, which showed 
that rice, oil, salt, and sugar consumption decreased in 
PLA villages. Process data suggested that intentional 
exercise increased, particularly among women. One 
striking efect of the groups that emerged through 
process evaluation was that women were able to negotiate 
time for group exercise in communities where individual 
women were stigmatised if they walked alone. Messages 
alone might not be able to change this behaviour.30 
Furthermore, the removal of stigma about diabetes, the 
increased solidarity among villagers, and the sharing of 
information and ideas might have reduced stress levels 
in the population, which might have contributed to the 
PLA intervention efect. The diferences between process 
and survey data require further research. The tools we 
used to measure food consumption and exercise might 
be too blunt, and participants might be able to more 
accurately estimate their time spent exercising and 
quantities of food eaten after the intervention given the 
clear messaging and emphasis on these behaviours.
Our approach and some of the assumptions we used for 
calculating DALYs gives a conservative estimate of the 
total DALYs averted by PLA. The disability weight that we 
used, though very small, is for uncomplicated type 2 
diabetes. We used the same weight for both type 2 diabetes 
and intermediate hyperglycaemia, which might slightly 
overestimate the years lived with disability. However, we 
did not take into account the likelihood that some of the 
individuals with type 2 diabetes will develop diabetes-
related complications, for which disability weights can 
range from 0·004 to 0·631.31 Additionally, since we did not 
have the exact age of diagnosis or onset of diabetes, we 
used average age of individuals with diagnosed diabetes in 
our end-of-study survey as age of onset (or diagnosis) of 
diabetes. Using this age is likely to underestimate years 
lived with disability and years of life lost, since many 
individuals were diagnosed before this age.
As previously noted, our population-level evaluation 
means we are unable to estimate QALYs gained. However, 
the cost-efectiveness ratios of INT$316 to $6518 per 
case of intermediate hyperglycaemia or type 2 diabetes 
prevented (or $124 to $2551 per DALY averted) suggests 
that PLA is highly cost-efective according to the WHO 
cost-efectiveness threshold,32 considering Bangladesh’s 
gross domestic product per person of $3869 (in 2017). 
Scale-up of PLA at the national level could prevent 
about 240 000 cases of type 2 diabetes or intermediate 
hyperglycaemia each year (equivalent to about $132 million 
savings in health-care costs per year), assuming a 30% loss 
in efect through scale-up (appendix). In the absence of 
prepayment systems in Bangladesh, most health-care 
expenditures are incurred by patients and their 
households, potentially leading to inancial catastrophes 
for many.33 Preliminary analyses of our baseline survey 
data on cost of seeking care suggests that about 60% of 
people with type 2 diabetes might be at risk of catastrophic 
and impoverishing health expenditure (ie, spend more 
than 10% of their household income on diabetes care). 
Therefore, scaling up cost-efective interventions such as 
the DMagic PLA has potential to reduce the incidence of 
impoverishing health expenditure.
The strengths of our study are the large, rural, 
population-based surveys with high response rates at 
baseline and the end of the study, and the high 2-year 
follow-up of the intermediate hyperglycaemia cohort, 
and assessment of glycaemic status through fasting and 
2 h blood glucose tests. Randomisation should eliminate 
issues of confounding, although baseline diferences in 
wealth were apparent and therefore controlled for, but 
the possibility of additional unmeasured imbalances 
between study groups cannot be excluded. Enumerator 
and participant masking to intervention exposure was 
infeasible in the end-of-study survey, although the extent 
to which this could afect the primary outcome measures 
is likely to be small and we identiied no enumerator bias 
in our sensitivity analysis. Both interventions had good 
coverage and there was minimal contamination between 
groups. Although capillary blood glucose concentrations 
overestimate blood sugar compared with venous samples, 
the method is feasible and acceptable for epidemiological 
studies and would not afect the diferences we identiied 
between study intervention groups.
Further analysis of process evaluation data is likely to 
provide a more nuanced understanding of intervention 
mechanisms and efects. Nevertheless, the large, cost-
efective impact of PLA in this trial suggests that it might 
be beneicial in other LMICs with a high burden of type 2 
diabetes, and perhaps among high-risk groups in high-
income settings. Replication in other populations is an 
important next step and follow-up of the DMagic study 
population with mixed-methods approaches will be 
important to better explain intervention mechanisms of 
action and long-term impacts.
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